Tracker › Companies › Harvard Bioscience INC
3 No sign of it. We found no public evidence tying Harvard Bioscience INC's cuts to AI.
Every tracked 2026 layoff at Harvard Bioscience INC, newest first. Scores are 0–100: how strongly the public evidence ties the cuts to AI. Sources are linked on each one.
AI score 3/100 (Minimal) · 80% interval 2–3 · evidence grade D · US · Instruments / Medical Devices
Stated reason: On January 23, 2026, the Board of Directors of Harvard Bioscience, Inc. (the “Company”) approved management’s comprehensive plan, referred to as Project Viking, for the strategic consolidation of its manufacturing operations to improve efficiency and support long-term growth. The Company will close its manufacturing facility in Holliston, MA and transition U.S. production to its manufacturing hub in Minneapolis, MN. …
Why 3: Plant, store or site closure · Drivers: contrary evidence −0.7, industry AI exposure +0.5
Evidence: SEC filing. Signals: attribution 0.0, primary source 0.0, exec statement 0.0, role exposure 0.474, industry exposure 0.712, AI investment 0.0, contrary evidence 0.4 · named roles: Computer and Information Systems Managers, General and Operations Managers, Machinists, Production Workers, All Other
Headcount basis: not disclosed
Scores are evidence-based estimates from a published model, not findings that AI caused any layoff. Spot something wrong or missing? Tell us.
Other Health Care & Pharma layoffs we track.
Health Care & Pharma · 3,800 workers
Health Care & Pharma · 648 workers
Health Care & Pharma · 419 workers
Health Care & Pharma · 365 workers
Health Care & Pharma · 300 workers
Health Care & Pharma · 120 workers
